Atrion Corp (ATRI): Emile A Battat , Chairman of Atrion Corp sold 12 shares on Jun 23, 2016. The Insider selling transaction was reported by the company on Jun 24, 2016 to the Securities and Exchange Commission. The shares were sold at $432.00 per share for a total value of $5,184.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 23, 2016, Emile A Battat (Chairman) sold 72 shares at $427.50 per share price.On Jun 20, 2016, Jeffery Strickland (CFO) sold 1,000 shares at $425.70 per share price.Also, On Aug 27, 2015, Ronald Nicholas Spaulding (director) sold 500 shares at $375.90 per share price.
Shares of Atrion Corporation (ATRI) ended Friday, Jun 24, 2016 session in red amid volatile trading. The shares closed down -4.14 points or -0.96% at $425.86 with 10,526 shares getting traded. Post opening the session at $425.035, the shares hit an intraday low of $424.9922 and an intraday high of $429.1 and the price vacillated in this range throughout the day. The company has a market cap of $775 M and the number of outstanding shares has been calculated to be 18,20,402 shares. The 52-week high of Atrion Corporation is $433 and the 52-week low is $343.4999.
Company has been under the radar of several Street Analysts.Atrion Corporation is Initiated by BWS Financial to Sell and the brokerage firm has set the Price Target at $300. The Rating was issued on Apr 25, 2016.
Atrion Corporation (Atrion) develops and manufactures products primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. The Company’s fluid delivery products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill hold and release controlled amounts of fluids or gasses on demand for use in various intubation catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes and produce specialized intravenous sets for use in numerous applications including anesthesia and oncology. The Company’s principal cardiovascular product is the Myocardial Protection System (MPS2) a technology that delivers essential fluids and medications to the heart during open-heart surgery.